Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Sep 2020
Price :
$35
*
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Allergan
- 17 Jul 2019 Status changed from recruiting to discontinued.
- 11 Apr 2019 Planned End Date changed from 29 Feb 2020 to 22 Feb 2020.
- 11 Apr 2019 Planned primary completion date changed from 29 Feb 2020 to 22 Feb 2020.